<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03155139</url>
  </required_header>
  <id_info>
    <org_study_id>PA-China 2017</org_study_id>
    <nct_id>NCT03155139</nct_id>
  </id_info>
  <brief_title>Primary Aldosteronism In Hypertensive Patients in China</brief_title>
  <acronym>PA-China</acronym>
  <official_title>Primary Aldosteronism In Hypertensive Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qifu Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fu Wai Hospital, Beijing, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the prevalence of primary aldosteronism (PA) in Chinese patients with
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a nationwide sampling study. To investigate the prevalence of primary aldosteronism
      (PA) in Chinese patients with hypertension, we will conduct a case detection of PA in Chinese
      hypertensive patients from 10 centers of China (including Beijing, Chongqing, Shanghai,
      Guangzhou, et al.); furthermore, a case confirmation of PA (captopril challenge test and
      saline infusion test) will be performed if the result of case detection is positive. This
      study will be completed in two years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with newly diagnosed hypertension</measure>
    <time_frame>2 years</time_frame>
    <description>To calculate the prevalence of PA in Chinese patients with hypertension</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with confirmed primary aldosteronism (PA)</measure>
    <time_frame>2 years</time_frame>
    <description>To calculate the prevalence of PA in Chinese patients with hypertension</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of PA</measure>
    <time_frame>2 years</time_frame>
    <description>Prevalence of PA= Number of PA / Number of subjects with hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age</measure>
    <time_frame>2 years</time_frame>
    <description>Characteristics of PA in Chinese patients with hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 years</time_frame>
    <description>Characteristics of PA in Chinese patients with hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Family history of hypertension</measure>
    <time_frame>2 years</time_frame>
    <description>Characteristics of PA in Chinese patients with hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>2 years</time_frame>
    <description>Characteristics of PA in Chinese patients with hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>2 years</time_frame>
    <description>Characteristics of PA in Chinese patients with hypertension</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Hyperaldosteronism; Primary</condition>
  <condition>Hypertension Secondary</condition>
  <arm_group>
    <arm_group_label>Patients without primary aldosteronism (PA)</arm_group_label>
    <description>PA case detection or confirmatory tests was negative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with primary aldosteronism (PA)</arm_group_label>
    <description>PA case detection and confirmatory tests were positive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Aldosterone/renin ratio (ARR) testing</intervention_name>
    <description>Plasma aldosterone concentration tests, Direct renin concentration tests</description>
    <arm_group_label>Patients without primary aldosteronism (PA)</arm_group_label>
    <arm_group_label>Patients with primary aldosteronism (PA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Confirmatory tests</intervention_name>
    <description>Captopril challenge test, Saline infusion test</description>
    <arm_group_label>Patients with primary aldosteronism (PA)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Some subtye of PA such as glucocorticoid remediable aldosteronism(GRA) should be diagnosed by
      DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sampling Design: hypertensive patients will be continuously sampled for case detection in
        each center. PASS 11.0 Software-Confidence Intervals for One Proportion was used to
        calculate the sample size. A sample size of 2928 produces a two-sided 95% confidence
        interval with a width equal to 0.02 when the sample proportion(prevalence of PA) is 0.080.
        Accounting for the 20% withdraw rate in the process of case detection, the final sample
        size should be 3635 (about 4000 cases).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed hypertension(with a course less than six months);

          2. Drug negative, or voluntary to discontinue/change the anti-hypertensive medications;

          3. Aged between 18-80 year, gender is not limited;

          4. Voluntary to sign on the informed consent.

        Exclusion Criteria:

          1. patients with severe cardiac, hepatic or renal dysfunction;

          2. suspicious or confirmed other types of secondary hypertension, including Cushing's
             syndrome, pheochromocytoma and renal artery stenosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Cai, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifu Li, phD</last_name>
    <phone>+86 023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shumin Yang, phD</last_name>
    <phone>+86 023-89011552</phone>
    <email>443068494@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, PhD</last_name>
      <phone>+86 23 89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Li X, Goswami R, Yang S, Li Q. Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2016 Aug 17;17(3). pii: 1470320316657450. doi: 10.1177/1470320316657450. Print 2016 Jul.</citation>
    <PMID>27534428</PMID>
  </results_reference>
  <results_reference>
    <citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.</citation>
    <PMID>26934393</PMID>
  </results_reference>
  <results_reference>
    <citation>KÃ¤yser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, Hermus AR, Lenders JW, Deinum J. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab. 2016 Jul;101(7):2826-35. doi: 10.1210/jc.2016-1472. Epub 2016 May 12. Review.</citation>
    <PMID>27172433</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>prevalence</keyword>
  <keyword>primary aldosteronism</keyword>
  <keyword>hypertension</keyword>
  <keyword>nationwide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

